Ann: TGA registration for superbug detection kits, page-10

All companies have running costs staff costs and so on. Some don't even have any revenue and rely on crs. So when I see productions costs 5 times less of revenue pulled in then that is a good indicator things can change fast in terms of company value rerate. There is not much on offer to buy either so when the market wants in the price of shares will sky rocket imo. In saying that if this was a company with 1billion shares. Trading at 3c... with the same revenue and product suite I think it would rerated big time. Little does the market know there is not many shares on issue. And more than 80% held by top 20. Directors buying more on market at 25c and 29c. Imo only a matter of time before shares are significantly higher than now. And who's to say when profits will be in. When a cr is due. And when dividends are paid. That is anyone's speculation. Plenty of money in the bank no debt. Hospitals in place and new products progressing...giving gss a real opportunity to strike some serious ongoing revenue.

The small volume sales that reduced share w price to 25c was good to buy more and flush out short termers. Seems to have worked